Free Trial

Cytek Biosciences (CTKB) Financials

Cytek Biosciences logo
$3.86 +0.09 (+2.39%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$3.86 0.00 (-0.03%)
As of 04/28/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Cytek Biosciences

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
2.58 -12 -6.02
Consolidated Net Income / (Loss)
2.48 -12 -6.02
Net Income / (Loss) Continuing Operations
2.48 -12 -6.02
Total Pre-Tax Income
1.26 -16 -5.70
Total Operating Income
-1.80 -28 -21
Total Gross Profit
101 109 111
Total Revenue
164 193 200
Operating Revenue
164 193 200
Total Cost of Revenue
63 84 89
Operating Cost of Revenue
63 84 89
Total Operating Expenses
103 137 132
Selling, General & Admin Expense
35 44 43
Marketing Expense
33 49 49
Research & Development Expense
35 44 39
Total Other Income / (Expense), net
3.06 12 15
Interest Expense
2.57 2.07 -5.24
Interest & Investment Income
4.62 6.41 5.12
Other Income / (Expense), net
1.02 7.79 4.46
Income Tax Expense
-1.22 -3.56 0.32
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.09 0.00 0.00
Weighted Average Basic Shares Outstanding
134.51M 135.28M 130.61M
Weighted Average Diluted Shares Outstanding
138.56M 135.28M 130.61M
Weighted Average Basic & Diluted Shares Outstanding
135.43M 130.82M 128.10M

Quarterly Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
1.67 3.53 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Consolidated Net Income / (Loss)
1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Net Income / (Loss) Continuing Operations
1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Total Pre-Tax Income
1.85 4.11 -9.04 -6.60 -4.19 4.11 -8.99 -7.19 0.16 10
Total Operating Income
1.36 0.08 -12 -9.13 -6.42 -0.14 -11 -8.53 -4.25 2.99
Total Gross Profit
27 29 21 28 27 33 23 25 29 34
Total Revenue
40 48 37 50 48 58 45 47 52 57
Operating Revenue
40 48 37 50 48 58 45 47 52 57
Total Cost of Revenue
14 19 16 22 21 25 22 21 22 24
Operating Cost of Revenue
14 19 16 22 21 25 22 21 22 24
Total Operating Expenses
26 29 33 37 34 33 34 34 33 31
Selling, General & Admin Expense
8.04 11 12 11 10 11 11 12 11 9.07
Marketing Expense
8.81 9.03 11 14 12 12 13 12 12 12
Research & Development Expense
8.65 9.75 9.97 12 11 11 9.80 10 9.88 9.72
Total Other Income / (Expense), net
0.49 4.03 3.12 2.53 2.24 4.25 1.74 1.34 4.41 7.34
Interest Expense
0.65 0.69 0.67 0.41 0.60 0.39 0.44 0.13 0.12 -5.93
Interest & Investment Income
1.58 2.63 2.14 1.20 1.62 1.45 1.36 1.42 1.43 0.91
Other Income / (Expense), net
-0.45 2.09 1.65 1.74 1.21 3.19 0.82 0.06 3.09 0.49
Income Tax Expense
0.22 0.40 -2.23 -2.21 2.27 -1.39 -2.82 3.25 -0.78 0.68
Weighted Average Basic Shares Outstanding
134.71M 134.51M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 131.00M 130.61M
Weighted Average Diluted Shares Outstanding
138.71M 138.56M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 132.79M 130.61M
Weighted Average Basic & Diluted Shares Outstanding
134.85M 135.43M 135.67M 136.36M 135.55M 130.82M 131.27M 131.51M 128.81M 128.10M

Annual Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-65 -132 -69
Net Cash From Operating Activities
-12 5.28 25
Net Cash From Continuing Operating Activities
-12 7.48 25
Net Income / (Loss) Continuing Operations
2.48 -12 -6.02
Consolidated Net Income / (Loss)
2.48 -12 -6.02
Depreciation Expense
2.49 6.05 7.21
Amortization Expense
3.09 - -1.93
Non-Cash Adjustments To Reconcile Net Income
17 21 18
Changes in Operating Assets and Liabilities, net
-38 -7.10 8.03
Net Cash From Investing Activities
-56 -94 -83
Net Cash From Continuing Investing Activities
-56 -94 -83
Purchase of Property, Plant & Equipment
-9.75 -4.69 -3.53
Acquisitions
-0.12 -45 -0.68
Purchase of Investments
-46 -176 -274
Sale of Property, Plant & Equipment
0.00 0.00 0.29
Sale and/or Maturity of Investments
0.00 132 195
Net Cash From Financing Activities
5.51 -42 -16
Net Cash From Continuing Financing Activities
5.51 -44 -16
Repayment of Debt
-0.05 -0.57 -0.56
Repurchase of Common Equity
0.00 -44 -22
Issuance of Debt
2.98 0.00 4.18
Other Financing Activities, net
2.58 1.05 2.17
Effect of Exchange Rate Changes
-2.49 - 4.53
Cash Income Taxes Paid
10 5.31 3.83

Quarterly Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-8.37 -42 -167 -0.85 33 3.38 1.51 8.78 -16 -64
Net Cash From Operating Activities
-7.50 6.19 2.86 -2.85 -4.24 9.51 3.96 6.20 13 2.00
Net Cash From Continuing Operating Activities
-7.50 6.19 3.45 -3.44 -4.24 12 3.96 6.20 13 2.00
Net Income / (Loss) Continuing Operations
1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Consolidated Net Income / (Loss)
1.63 3.72 -6.81 -4.39 -6.46 5.50 -6.17 -10 0.94 9.64
Depreciation Expense
0.07 0.76 1.00 1.65 1.77 1.63 1.70 1.81 1.85 1.85
Amortization Expense
0.70 1.03 - - -0.77 - -0.44 -0.51 -0.29 -0.69
Non-Cash Adjustments To Reconcile Net Income
5.90 3.14 4.50 7.56 6.49 2.13 7.02 7.23 7.46 -3.62
Changes in Operating Assets and Liabilities, net
-16 -2.46 4.75 -6.15 -5.27 -0.43 1.85 8.11 3.26 -5.18
Net Cash From Investing Activities
-1.15 -51 -169 2.79 43 29 -5.75 2.02 -16 -63
Net Cash From Continuing Investing Activities
-1.15 -51 -169 2.69 43 29 -5.75 2.02 -16 -63
Purchase of Property, Plant & Equipment
-1.11 -6.53 -0.64 -1.17 -1.33 -1.54 -0.57 -1.05 -1.01 -0.89
Acquisitions
-0.04 -0.08 -45 -0.06 -0.06 -0.06 -0.06 -0.15 0.01 -0.48
Purchase of Investments
- -44 -123 -6.08 -23 -23 -77 -37 -53 -107
Sale of Property, Plant & Equipment
- - - - - - - - 0.02 0.19
Sale and/or Maturity of Investments
- - 0.00 10 68 54 72 40 38 45
Net Cash From Financing Activities
0.16 3.85 0.00 0.22 -8.27 -34 1.61 -1.71 -12 -3.64
Net Cash From Continuing Financing Activities
0.16 3.85 0.00 0.22 -8.27 -36 1.61 -1.71 -12 -3.64
Repayment of Debt
- -0.05 -0.15 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14
Repurchase of Common Equity
- - - - -8.43 -35 - - -12 -6.99
Issuance of Debt
- - 0.00 - - - 1.39 -0.00 0.01 2.79
Other Financing Activities, net
0.16 0.92 0.15 0.37 0.29 0.24 0.36 0.09 0.00 1.71
Effect of Exchange Rate Changes
0.13 -1.00 - - - - 1.70 2.26 -0.94 1.52
Cash Income Taxes Paid
2.27 0.46 0.09 0.59 0.13 4.50 0.00 1.06 0.86 1.91

Annual Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
519 494 500
Total Current Assets
454 392 396
Cash & Equivalents
297 167 99
Restricted Cash
2.90 0.33 0.03
Short-Term Investments
45 95 179
Accounts Receivable
49 56 61
Inventories, net
48 61 44
Prepaid Expenses
13 13 14
Plant, Property, & Equipment, net
14 18 18
Total Noncurrent Assets
52 84 85
Goodwill
10 16 17
Intangible Assets
4.33 23 20
Noncurrent Deferred & Refundable Income Taxes
20 30 33
Other Noncurrent Operating Assets
17 14 15
Total Liabilities & Shareholders' Equity
519 494 500
Total Liabilities
94 101 104
Total Current Liabilities
49 56 68
Accounts Payable
4.81 3.03 5.53
Accrued Expenses
21 20 21
Current Deferred Revenue
13 23 25
Other Current Liabilities
10 10 15
Total Noncurrent Liabilities
45 45 36
Asset Retirement Reserve & Litigation Obligation
16 16 9.04
Noncurrent Deferred Revenue
13 15 16
Other Noncurrent Operating Liabilities
16 14 11
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
426 393 396
Total Preferred & Common Equity
426 393 396
Total Common Equity
426 393 396
Common Stock
443 424 431
Retained Earnings
-17 -29 -35
Accumulated Other Comprehensive Income / (Loss)
-0.70 -1.28 0.02

Quarterly Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
499 525 525 519 492 484 491
Total Current Assets
444 426 425 422 389 384 390
Cash & Equivalents
342 129 132 164 169 178 162
Restricted Cash
0.00 2.92 0.00 0.00 0.35 0.03 0.03
Short-Term Investments
- 170 167 124 101 99 116
Accounts Receivable
40 43 50 55 50 45 53
Inventories, net
49 70 66 67 55 50 47
Prepaid Expenses
13 11 11 12 13 12 13
Plant, Property, & Equipment, net
7.84 16 16 17 18 18 19
Total Noncurrent Assets
48 83 85 80 85 82 83
Goodwill
10 19 19 16 16 16 16
Intangible Assets
4.49 25 24 24 22 21 20
Noncurrent Deferred & Refundable Income Taxes
14 23 26 24 33 30 31
Other Noncurrent Operating Assets
19 16 15 15 14 14 15
Total Liabilities & Shareholders' Equity
499 525 525 519 492 484 491
Total Liabilities
83 101 101 104 99 95 106
Total Current Liabilities
41 57 54 59 56 52 63
Accounts Payable
5.64 5.28 3.08 4.71 3.73 3.19 5.39
Accrued Expenses
17 20 20 21 18 15 21
Current Deferred Revenue
12 18 21 23 23 24 25
Other Current Liabilities
7.12 13 10 10 11 9.73 11
Total Noncurrent Liabilities
41 45 47 45 44 42 43
Asset Retirement Reserve & Litigation Obligation
15 16 16 16 17 17 17
Noncurrent Deferred Revenue
10 13 16 15 15 14 15
Other Noncurrent Operating Liabilities
16 16 15 14 12 11 11
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
417 423 424 416 393 389 385
Total Preferred & Common Equity
417 423 424 416 393 389 385
Total Common Equity
417 423 424 416 393 389 385
Common Stock
438 448 454 452 430 435 430
Retained Earnings
-21 -24 -28 -35 -35 -46 -45
Accumulated Other Comprehensive Income / (Loss)
-0.53 -0.59 -1.76 -1.58 -1.55 -0.20 0.10

Annual Metrics and Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
28.20% 17.67% 3.85%
EBITDA Growth
-45.94% -391.97% 23.01%
EBIT Growth
-110.30% -2,451.02% 19.90%
NOPAT Growth
-176.19% -448.06% 26.30%
Net Income Growth
-17.94% -589.05% 50.44%
EPS Growth
0.00% 0.00% 0.00%
Operating Cash Flow Growth
-364.17% 143.18% 380.57%
Free Cash Flow Firm Growth
-85.09% -54.26% 97.23%
Invested Capital Growth
99.91% 59.91% -9.57%
Revenue Q/Q Growth
25.87% 5.41% -0.38%
EBITDA Q/Q Growth
123.01% 20.47% -13.62%
EBIT Q/Q Growth
96.90% 4.22% 2.54%
NOPAT Q/Q Growth
78.56% -0.80% 13.20%
Net Income Q/Q Growth
203.54% 12.81% 40.74%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
5.74% 169.16% -22.85%
Free Cash Flow Firm Q/Q Growth
0.00% 4.92% -157.34%
Invested Capital Q/Q Growth
8.68% 2.21% 9.47%
Profitability Metrics
- - -
Gross Margin
61.56% 56.69% 55.43%
EBITDA Margin
2.92% -7.25% -5.38%
Operating Margin
-1.10% -14.43% -10.24%
EBIT Margin
-0.48% -10.39% -8.01%
Profit (Net Income) Margin
1.51% -6.29% -3.00%
Tax Burden Percent
197.14% 77.33% 105.61%
Interest Burden Percent
-160.31% 78.35% 35.49%
Effective Tax Rate
-97.14% 0.00% 0.00%
Return on Invested Capital (ROIC)
-5.82% -18.40% -11.58%
ROIC Less NNEP Spread (ROIC-NNEP)
-7.52% -20.82% -14.67%
Return on Net Nonoperating Assets (RNNOA)
6.42% 15.44% 10.05%
Return on Equity (ROE)
0.60% -2.97% -1.53%
Cash Return on Invested Capital (CROIC)
-72.45% -64.50% -1.52%
Operating Return on Assets (OROA)
-0.16% -3.96% -3.23%
Return on Assets (ROA)
0.51% -2.40% -1.21%
Return on Common Equity (ROCE)
0.60% -2.97% -1.53%
Return on Equity Simple (ROE_SIMPLE)
0.58% -3.09% -1.52%
Net Operating Profit after Tax (NOPAT)
-3.56 -19 -14
NOPAT Margin
-2.17% -10.10% -7.17%
Net Nonoperating Expense Percent (NNEP)
1.70% 2.42% 3.09%
Return On Investment Capital (ROIC_SIMPLE)
-0.84% -4.96% -3.63%
Cost of Revenue to Revenue
38.44% 43.31% 44.57%
SG&A Expenses to Revenue
21.15% 22.78% 21.51%
R&D to Revenue
21.25% 22.87% 19.66%
Operating Expenses to Revenue
62.66% 71.12% 65.67%
Earnings before Interest and Taxes (EBIT)
-0.79 -20 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4.80 -14 -11
Valuation Ratios
- - -
Price to Book Value (P/BV)
3.24 3.15 2.11
Price to Tangible Book Value (P/TBV)
3.35 3.49 2.33
Price to Revenue (P/Rev)
8.39 6.40 4.17
Price to Earnings (P/E)
534.49 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.19% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
12.67 7.47 4.74
Enterprise Value to Revenue (EV/Rev)
6.30 5.04 2.78
Enterprise Value to EBITDA (EV/EBITDA)
215.35 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 184.33 21.99
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.85 -0.74 -0.69
Leverage Ratio
1.18 1.24 1.26
Compound Leverage Factor
-1.90 0.97 0.45
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
10.00 8.30 5.82
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
9.26 6.97 5.86
Quick Ratio
7.95 5.66 5.00
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-44 -68 -1.89
Operating Cash Flow to CapEx
-125.47% 112.65% 784.03%
Free Cash Flow to Firm to Interest Expense
-17.21 -32.99 0.00
Operating Cash Flow to Interest Expense
-4.75 2.55 0.00
Operating Cash Flow Less CapEx to Interest Expense
-8.54 0.29 0.00
Efficiency Ratios
- - -
Asset Turnover
0.33 0.38 0.40
Accounts Receivable Turnover
4.17 3.68 3.44
Inventory Turnover
1.57 1.53 1.71
Fixed Asset Turnover
16.80 12.03 11.02
Accounts Payable Turnover
16.09 21.33 20.87
Days Sales Outstanding (DSO)
87.47 99.08 106.08
Days Inventory Outstanding (DIO)
232.46 238.05 214.00
Days Payable Outstanding (DPO)
22.69 17.11 17.49
Cash Conversion Cycle (CCC)
297.25 320.02 302.60
Capital & Investment Metrics
- - -
Invested Capital
81 130 118
Invested Capital Turnover
2.68 1.82 1.62
Increase / (Decrease) in Invested Capital
41 49 -12
Enterprise Value (EV)
1,033 973 558
Market Capitalization
1,377 1,236 836
Book Value per Share
$3.16 $2.90 $3.07
Tangible Book Value per Share
$3.05 $2.61 $2.79
Total Capital
426 393 396
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-344 -263 -278
Capital Expenditures (CapEx)
9.75 4.69 3.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)
61 73 51
Debt-free Net Working Capital (DFNWC)
405 336 329
Net Working Capital (NWC)
405 336 329
Net Nonoperating Expense (NNE)
-6.04 -7.34 -8.35
Net Nonoperating Obligations (NNO)
-344 -263 -278
Total Depreciation and Amortization (D&A)
5.58 6.05 5.28
Debt-free, Cash-free Net Working Capital to Revenue
37.15% 37.87% 25.39%
Debt-free Net Working Capital to Revenue
246.88% 173.99% 164.02%
Net Working Capital to Revenue
246.88% 173.99% 164.02%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
134.51M 135.28M 130.61M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
138.56M 135.28M 130.61M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
135.43M 130.82M 128.10M
Normalized Net Operating Profit after Tax (NOPAT)
-1.26 -19 -14
Normalized NOPAT Margin
-0.77% -10.10% -7.17%
Pre Tax Income Margin
0.77% -8.14% -2.84%
Debt Service Ratios
- - -
EBIT to Interest Expense
-0.31 -9.68 0.00
NOPAT to Interest Expense
-1.38 -9.41 0.00
EBIT Less CapEx to Interest Expense
-4.09 -11.95 0.00
NOPAT Less CapEx to Interest Expense
-5.17 -11.68 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -363.44% -358.99%

Quarterly Metrics and Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
17.75% 230.57% 5.77% 23.74% 18.59% 20.48% 20.96% -6.19% 7.29% -1.30%
EBITDA Growth
-37.39% 118.28% -654.08% -1,502.93% -349.94% 18.35% 9.00% -24.97% 109.63% -1.11%
EBIT Growth
-63.46% 109.73% -284.84% -545.15% -669.62% 40.60% 5.70% -14.63% 77.80% 13.67%
NOPAT Growth
-39.71% -99.87% -415.99% -924.35% -475.96% -339.81% 11.74% 6.57% -466.55% 1,632.15%
Net Income Growth
14.51% 419.14% -215.43% -525.07% -497.05% 48.01% 9.37% -137.78% 114.58% 75.21%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-746.34% 13.67% 293.11% 69.81% 43.51% 53.59% 38.45% 317.68% 411.89% -79.01%
Free Cash Flow Firm Growth
-93.80% 0.00% -82.73% -83.72% -20.36% -20.54% 90.44% 110.63% 90.15% 131.15%
Invested Capital Growth
183.78% 99.91% 170.49% 104.69% 70.04% 59.91% 0.52% -10.74% -15.57% -9.57%
Revenue Q/Q Growth
0.79% 19.42% -23.27% 33.99% -3.41% 21.32% -22.97% 3.92% 10.47% 11.60%
EBITDA Q/Q Growth
312.22% 134.99% -340.01% 39.66% 26.56% 211.27% -284.54% 17.13% 105.66% 1,042.12%
EBIT Q/Q Growth
179.91% 137.70% -583.22% 29.71% 29.44% 158.67% -424.10% 14.56% 86.34% 400.43%
NOPAT Q/Q Growth
291.65% -93.65% -11,314.47% 24.95% 29.66% 95.95% -4,027.33% 20.56% -326.56% 110.96%
Net Income Q/Q Growth
331.62% 128.66% -283.08% 35.54% -47.13% 185.24% -212.10% -69.14% 109.02% 924.65%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
20.51% 182.53% -53.85% -199.72% -48.74% 324.39% -58.40% 56.79% 113.10% -84.90%
Free Cash Flow Firm Q/Q Growth
-23.44% 14.17% -109.38% 17.19% 19.13% 14.04% 83.39% 192.00% -174.94% 371.97%
Invested Capital Q/Q Growth
22.46% 8.68% 49.14% 3.12% 1.72% 2.21% -6.25% -8.42% -3.78% 9.47%
Profitability Metrics
- - - - - - - - - -
Gross Margin
66.36% 60.77% 56.72% 56.67% 56.62% 56.75% 51.30% 54.56% 56.32% 58.55%
EBITDA Margin
4.17% 8.20% -25.64% -11.55% -8.78% 8.05% -19.29% -15.38% 0.79% 8.07%
Operating Margin
3.36% 0.17% -32.79% -18.37% -13.38% -0.23% -23.93% -18.29% -8.25% 5.20%
EBIT Margin
2.26% 4.50% -28.34% -14.87% -10.86% 5.25% -22.09% -18.17% -2.25% 6.05%
Profit (Net Income) Margin
4.02% 7.69% -18.35% -8.83% -13.45% 9.45% -13.75% -22.38% 1.83% 16.78%
Tax Burden Percent
87.89% 90.37% 75.30% 66.54% 154.27% 133.86% 68.60% 145.20% 599.36% 93.41%
Interest Burden Percent
202.19% 189.15% 86.01% 89.28% 80.30% 134.43% 90.74% 84.86% -13.57% 296.95%
Effective Tax Rate
12.11% 9.63% 0.00% 0.00% 0.00% -33.86% 0.00% 0.00% -499.36% 6.59%
Return on Invested Capital (ROIC)
7.59% 0.42% -45.79% -24.20% -16.93% -0.57% -27.60% -21.34% -84.60% 7.84%
ROIC Less NNEP Spread (ROIC-NNEP)
7.47% -0.61% -46.31% -24.82% -16.31% -2.44% -28.07% -19.79% -93.94% 5.30%
Return on Net Nonoperating Assets (RNNOA)
-6.55% 0.52% 37.03% 19.27% 12.34% 1.81% 19.69% 14.02% 66.36% -3.64%
Return on Equity (ROE)
1.04% 0.94% -8.76% -4.93% -4.59% 1.24% -7.91% -7.32% -18.25% 4.20%
Cash Return on Invested Capital (CROIC)
0.00% -72.45% -101.80% -83.61% -70.97% -64.50% -15.69% -3.89% 2.80% -1.52%
Operating Return on Assets (OROA)
0.62% 1.50% -9.31% -5.13% -3.90% 2.00% -8.73% -7.12% -0.89% 2.44%
Return on Assets (ROA)
1.10% 2.57% -6.03% -3.05% -4.84% 3.60% -5.43% -8.77% 0.73% 6.77%
Return on Common Equity (ROCE)
1.04% 0.94% -8.76% -4.93% -4.59% 1.24% -7.91% -7.32% -18.25% 4.20%
Return on Equity Simple (ROE_SIMPLE)
-0.58% 0.00% -0.51% -1.38% -3.35% 0.00% -2.93% -4.51% -2.64% 0.00%
Net Operating Profit after Tax (NOPAT)
1.20 0.08 -8.51 -6.39 -4.49 -0.18 -7.51 -5.97 -25 2.79
NOPAT Margin
2.95% 0.16% -22.95% -12.86% -9.36% -0.31% -16.75% -12.80% -49.44% 4.85%
Net Nonoperating Expense Percent (NNEP)
0.12% 1.03% 0.51% 0.62% -0.62% 1.87% 0.47% -1.55% 9.33% 2.54%
Return On Investment Capital (ROIC_SIMPLE)
- 0.02% - - - -0.05% - - - 0.70%
Cost of Revenue to Revenue
33.64% 39.23% 43.28% 43.33% 43.38% 43.25% 48.70% 45.44% 43.68% 41.45%
SG&A Expenses to Revenue
19.87% 21.75% 32.57% 21.71% 21.56% 18.47% 25.43% 25.09% 21.25% 15.78%
R&D to Revenue
21.37% 20.17% 26.89% 24.42% 23.27% 18.67% 21.84% 21.45% 19.19% 16.92%
Operating Expenses to Revenue
63.00% 60.60% 89.52% 75.04% 70.00% 56.98% 75.23% 72.86% 64.57% 53.35%
Earnings before Interest and Taxes (EBIT)
0.92 2.18 -11 -7.39 -5.21 3.06 -9.91 -8.47 -1.16 3.48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1.69 3.96 -9.51 -5.74 -4.21 4.69 -8.65 -7.17 0.41 4.64
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
4.76 3.24 2.94 2.73 1.81 3.15 2.24 1.88 1.89 2.11
Price to Tangible Book Value (P/TBV)
4.93 3.35 3.28 3.04 2.01 3.49 2.48 2.08 2.09 2.33
Price to Revenue (P/Rev)
15.21 8.39 7.49 6.60 4.11 6.40 4.37 3.70 3.62 4.17
Price to Earnings (P/E)
0.00 534.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
21.87 12.67 7.76 6.86 3.64 7.47 4.97 4.07 4.19 4.74
Enterprise Value to Revenue (EV/Rev)
12.59 6.30 5.68 4.90 2.54 5.04 3.03 2.30 2.24 2.78
Enterprise Value to EBITDA (EV/EBITDA)
0.00 215.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 236.84 184.33 95.20 29.50 13.70 21.99
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 136.73 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.88 -0.85 -0.80 -0.78 -0.76 -0.74 -0.70 -0.71 -0.71 -0.69
Leverage Ratio
1.16 1.18 1.22 1.22 1.22 1.24 1.25 1.24 1.26 1.26
Compound Leverage Factor
2.35 2.24 1.05 1.09 0.98 1.67 1.13 1.05 -0.17 3.74
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
15.54 10.01 8.42 7.95 5.41 8.46 6.35 5.69 5.21 5.95
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
10.70 9.26 7.53 7.93 7.20 6.97 6.99 7.33 6.21 5.86
Quick Ratio
9.19 7.95 6.05 6.50 5.85 5.66 5.77 6.14 5.26 5.00
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-47 -41 -85 -70 -57 -49 -8.14 7.49 -5.61 15
Operating Cash Flow to CapEx
-676.04% 94.84% 443.79% -242.76% -318.72% 617.66% 697.88% 589.17% 1,335.45% 284.07%
Free Cash Flow to Firm to Interest Expense
-72.98 -59.18 -126.49 -172.36 -95.82 -124.38 -18.46 55.90 -47.17 0.00
Operating Cash Flow to Interest Expense
-11.56 9.01 4.25 -6.97 -7.12 24.14 8.97 46.30 111.10 0.00
Operating Cash Flow Less CapEx to Interest Expense
-13.27 -0.49 3.29 -9.84 -9.36 20.23 7.69 38.44 102.78 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.27 0.33 0.33 0.35 0.36 0.38 0.40 0.39 0.40 0.40
Accounts Receivable Turnover
3.77 4.17 4.52 4.06 3.85 3.68 4.30 4.19 3.72 3.44
Inventory Turnover
1.49 1.57 1.20 1.26 1.33 1.53 1.44 1.54 1.60 1.71
Fixed Asset Turnover
20.32 16.80 15.06 15.32 14.50 12.03 11.88 11.73 11.20 11.02
Accounts Payable Turnover
11.93 16.09 11.42 14.27 14.95 21.33 19.85 28.39 17.96 20.87
Days Sales Outstanding (DSO)
96.75 87.47 80.78 89.83 94.72 99.08 84.90 87.01 97.99 106.08
Days Inventory Outstanding (DIO)
245.80 232.46 305.42 288.94 274.21 238.05 253.67 237.36 228.71 214.00
Days Payable Outstanding (DPO)
30.59 22.69 31.97 25.57 24.42 17.11 18.39 12.86 20.32 17.49
Cash Conversion Cycle (CCC)
311.96 297.25 354.24 353.20 344.51 320.02 320.18 311.52 306.38 302.60
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
75 81 122 125 128 130 122 112 108 118
Invested Capital Turnover
2.57 2.68 1.99 1.88 1.81 1.82 1.65 1.67 1.71 1.62
Increase / (Decrease) in Invested Capital
49 41 77 64 53 49 0.63 -13 -20 -12
Enterprise Value (EV)
1,640 1,033 943 860 465 973 607 455 451 558
Market Capitalization
1,982 1,377 1,245 1,159 753 1,236 878 733 729 836
Book Value per Share
$3.09 $3.16 $3.13 $3.13 $3.05 $2.90 $3.00 $2.96 $2.93 $3.07
Tangible Book Value per Share
$2.99 $3.05 $2.80 $2.81 $2.75 $2.61 $2.71 $2.68 $2.65 $2.79
Total Capital
417 426 423 424 416 393 393 389 385 396
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-342 -344 -302 -299 -288 -263 -270 -277 -278 -278
Capital Expenditures (CapEx)
1.11 6.53 0.64 1.17 1.33 1.54 0.57 1.05 0.99 0.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)
61 61 67 72 76 73 63 54 50 51
Debt-free Net Working Capital (DFNWC)
402 405 369 371 364 336 333 332 327 329
Net Working Capital (NWC)
402 405 369 371 364 336 333 332 327 329
Net Nonoperating Expense (NNE)
-0.43 -3.64 -1.71 -2.00 1.96 -5.69 -1.34 4.47 -26 -6.85
Net Nonoperating Obligations (NNO)
-342 -344 -302 -299 -288 -263 -270 -277 -278 -278
Total Depreciation and Amortization (D&A)
0.77 1.79 1.00 1.65 1.00 1.63 1.26 1.30 1.56 1.16
Debt-free, Cash-free Net Working Capital to Revenue
46.69% 37.15% 40.46% 41.23% 41.29% 37.87% 31.20% 27.55% 24.64% 25.39%
Debt-free Net Working Capital to Revenue
308.75% 246.88% 222.27% 211.41% 198.57% 173.99% 165.89% 167.77% 162.71% 164.02%
Net Working Capital to Revenue
308.75% 246.88% 222.27% 211.41% 198.57% 173.99% 165.89% 167.77% 162.71% 164.02%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
134.71M 134.51M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 131.00M 130.61M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
138.71M 138.56M 135.49M 135.92M 136.17M 135.28M 130.92M 131.44M 132.79M 130.61M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
134.85M 135.43M 135.67M 136.36M 135.55M 130.82M 131.27M 131.51M 128.81M 128.10M
Normalized Net Operating Profit after Tax (NOPAT)
1.20 0.08 -8.51 -6.39 -4.49 -0.10 -7.51 -5.97 -2.97 2.79
Normalized NOPAT Margin
2.95% 0.16% -22.95% -12.86% -9.36% -0.16% -16.75% -12.80% -5.77% 4.85%
Pre Tax Income Margin
4.57% 8.51% -24.37% -13.27% -8.72% 7.06% -20.05% -15.42% 0.30% 17.96%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
1.41 3.17 -15.62 -18.06 -8.76 7.76 -22.47 -63.19 -9.72 0.00
NOPAT to Interest Expense
1.84 0.11 -12.65 -15.62 -7.55 -0.46 -17.04 -44.54 -213.96 0.00
EBIT Less CapEx to Interest Expense
-0.30 -6.34 -16.57 -20.93 -11.00 3.85 -23.76 -71.05 -18.04 0.00
NOPAT Less CapEx to Interest Expense
0.13 -9.39 -13.61 -18.49 -9.79 -4.37 -18.32 -52.40 -222.28 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% -363.44% 0.00% -261.11% -485.89% -358.99%

Frequently Asked Questions About Cytek Biosciences' Financials

When does Cytek Biosciences's fiscal year end?

According to the most recent income statement we have on file, Cytek Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cytek Biosciences' net income changed over the last 2 years?

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$6.02 million in 2024, falling from $2.48 million in 2022. The previous period was -$12.15 million in 2023.

What is Cytek Biosciences's operating income?
Cytek Biosciences's total operating income in 2024 was -$20.52 million, based on the following breakdown:
  • Total Gross Profit: $111.11 million
  • Total Operating Expenses: $131.63 million
How has Cytek Biosciences revenue changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' total revenue changed from $164.04 million in 2022 to $200.45 million in 2024, a change of 22.2%.

How much debt does Cytek Biosciences have?

Cytek Biosciences' total liabilities were at $103.76 million at the end of 2024, a 2.3% increase from 2023, and a 10.5% increase since 2022.

How much cash does Cytek Biosciences have?

In the past 2 years, Cytek Biosciences' cash and equivalents has ranged from $98.72 million in 2024 to $296.60 million in 2022, and is currently $98.72 million as of their latest financial filing in 2024.

How has Cytek Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' book value per share changed from 3.16 in 2022 to 3.07 in 2024, a change of -2.6%.



This page (NASDAQ:CTKB) was last updated on 4/29/2025 by MarketBeat.com Staff
From Our Partners